Back to Search Start Over

Advancing drug discovery through assay development: a survey of tool compounds within the human solute carrier superfamily

Authors :
Daniela Digles
Alvaro Ingles-Prieto
Vojtech Dvorak
Tamara A. M. Mocking
Ulrich Goldmann
Andrea Garofoli
Evert J. Homan
Alberto Di Silvio
Lucia Azzollini
Francesca Sassone
Mario Fogazza
Felix Bärenz
Antje Pommereau
Yasmin Zuschlag
Jasper F. Ooms
Jeppe Tranberg-Jensen
Jesper S. Hansen
Josefina Stanka
Hubert J. Sijben
Helena Batoulis
Eckhard Bender
Riccardo Martini
Adriaan P. IJzerman
David B. Sauer
Laura H. Heitman
Vania Manolova
Juergen Reinhardt
Alexander Ehrmann
Philipp Leippe
Gerhard F. Ecker
Kilian V. M. Huber
Thomas Licher
Lia Scarabottolo
Tabea Wiedmer
Giulio Superti-Furga
Source :
Frontiers in Pharmacology, Vol 15 (2024)
Publication Year :
2024
Publisher :
Frontiers Media S.A., 2024.

Abstract

With over 450 genes, solute carriers (SLCs) constitute the largest transporter superfamily responsible for the uptake and efflux of nutrients, metabolites, and xenobiotics in human cells. SLCs are associated with a wide variety of human diseases, including cancer, diabetes, and metabolic and neurological disorders. They represent an important therapeutic target class that remains only partly exploited as therapeutics that target SLCs are scarce. Additionally, many small molecules reported in the literature to target SLCs are poorly characterized. Both features may be due to the difficulty of developing SLC transport assays that fulfill the quality criteria for high-throughput screening. Here, we report one of the main limitations hampering assay development within the RESOLUTE consortium: the lack of a resource providing high-quality information on SLC tool compounds. To address this, we provide a systematic annotation of tool compounds targeting SLCs. We first provide an overview on RESOLUTE assays. Next, we present a list of SLC-targeting compounds collected from the literature and public databases; we found that most data sources lacked specificity data. Finally, we report on experimental tests of 19 selected compounds against a panel of 13 SLCs from seven different families. Except for a few inhibitors, which were active on unrelated SLCs, the tested inhibitors demonstrated high selectivity for their reported targets. To make this knowledge easily accessible to the scientific community, we created an interactive dashboard displaying the collected data in the RESOLUTE web portal (https://re-solute.eu). We anticipate that our open-access resources on assays and compounds will support the development of future drug discovery campaigns for SLCs.

Details

Language :
English
ISSN :
16639812
Volume :
15
Database :
Directory of Open Access Journals
Journal :
Frontiers in Pharmacology
Publication Type :
Academic Journal
Accession number :
edsdoj.3ca8f18dbc2476ea3722a966b570ca6
Document Type :
article
Full Text :
https://doi.org/10.3389/fphar.2024.1401599